Literature DB >> 23504681

Significance of tumor size in renal cell cancer with perinephric fat infiltration: is TNM staging system adequate for predicting prognosis?

Evren Süer1, Sümer Baltaci, Berk Burgu, Özgü Aydoğdu, Çağatay Göğüş.   

Abstract

PURPOSE: To evaluate the influence of perinephric fat infiltration and tumor size on survival of patients with renal cell carcinoma (RCC).
MATERIALS AND METHODS: We have retrospectively reviewed the records of 338 consecutive patients with pT1-3aN0M0 RCC, including 275 pT1-2 and 63 pT3a tumors, who underwent open partial or radical nephrectomy between 1995 and 2008. Univariate and multivariate analyses were performed in order to evaluate the prognostic factors.
RESULTS: Median follow-up period was 36.07 months. Receiver Operating Characteristic curve analysis determined the optimal tumor size cutoff value as 7 cm (Area Under the Curve: 0.65 ± 0.047; 95% Confidence Interval: 0.558 to 0.741). Perinephric fat invasion and Fuhrman grade were independent prognostic factors for disease-specific survival (DSS). In patients with tumor size >7 cm, perinephric fat invasion affected DSS significantly. Tumor size (according to the cutoff value of 7 cm) significantly affected DSS in patients with pT3a disease. According to the TNM 2002 staging system, perinephric fat invasion did not have any significant effect on DSS in patients with tumor size smaller than 4 cm, unlike tumor size of 4 to 7 cm and >7 cm. pT3a tumors larger than 7 cm demonstrated the worst prognosis compared to other groups.
CONCLUSION: Perinephric fat invasion was demonstrated as a significant prognostic factor for RCC patients with tumor size >4 cm. Consequently, evaluation of pT3a patients should take tumor size into consideration for better prognostic analysis.

Entities:  

Mesh:

Year:  2013        PMID: 23504681

Source DB:  PubMed          Journal:  Urol J        ISSN: 1735-1308            Impact factor:   1.510


  7 in total

1.  Diagnostic potential of multidetector computed tomography for characterizing small renal masses.

Authors:  Maria Elisabetta Mancini; Annamaria Albergo; Marco Moschetta; Mariacristina Angelelli; Arnaldo Scardapane; Giuseppe Angelelli
Journal:  ScientificWorldJournal       Date:  2015-04-09

2.  Effect of perineoplasm perinephric adipose tissues on migration of clear cell renal cell carcinoma cells: a potential role of WNT signaling.

Authors:  Xiaolin Zi; Achim Lusch; Christopher A Blair; Zhamshid Okhunov; Noriko N Yokoyama; Shuman Liu; Molly Baker; Victor Huynh; Jaime Landman
Journal:  Oncotarget       Date:  2016-08-16

3.  miR-502-mediated histone methyltransferase SET8 expression is associated with clear cell renal cell carcinoma risk.

Authors:  Shenglei Zhang; Zhanjun Guo; Jinsheng Xu; Jing Wang; Junxia Zhang; Liwen Cui; Huiran Zhang; Yueping Liu; Yaling Bai
Journal:  Oncol Lett       Date:  2017-10-02       Impact factor: 2.967

4.  Development and internal validation of nomograms for the prediction of postoperative survival of patients with grade 4 renal cell carcinoma (RCC).

Authors:  Jun Zhu; Zhifu Liu; Zhongyuan Zhang; Yu Fan; Yuke Chen; Zhisong He; Liqun Zhou; Jie Jin; Cheng Shen; Wei Yu
Journal:  Transl Androl Urol       Date:  2020-12

5.  Association of Extrarenal Invasion Patterns and Tumor Size with the Differences in Survival Outcomes of T3a Renal Cell Carcinoma: A Proposal Modified T3a Stage System is Needed.

Authors:  XiaoFei Wu; Qiong Wang; Zhixian Wang; Xian Zhao; XiaoJing Xu
Journal:  Int J Gen Med       Date:  2022-01-07

6.  Influence of tumor size on oncological outcomes of pathological T3aN0M0 renal cell carcinoma treated by radical nephrectomy.

Authors:  Luyao Chen; Xin Ma; Hongzhao Li; Liangyou Gu; Xintao Li; Yu Gao; Yongpeng Xie; Xu Zhang
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

7.  Increased UCP1 expression in the perirenal adipose tissue of patients with renal cell carcinoma.

Authors:  Xueqin Li; Gongcheng Wang; Juan Liu; Guoxian Ding
Journal:  Oncol Rep       Date:  2019-09-10       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.